Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Neoadjuvant therapy in the treatment of breast cancer is not only a means of breast conserving surgery, but also a sensitive scheme for patients, in order to reduce the treatment grade, low toxicity and high efficiency. Chemotherapy combined with trastuzumab and pertuzumab is the standard neoadjuvant therapy for HER2 positive breast cancer patients. Paclitaxel plus carboplatin (TCb) is the first choice of chemotherapy recommended by major guidelines; As an alternative, single drug Taxus (T) is also listed as class I recommendation in the latest CSCO guidelines, but the level of evidence is slightly insufficient. In the HER2 positive neoadjuvant therapy population, relatively early and low-risk patients may obtain good curative effect in the treatment of single drug taxane chemotherapy combined with double target therapy. The project plans to adopt an ambispective cohort study, based on the large sample breast disease cohort database established by the breast center of Peking University People's Hospital, and retrospectively include the HER2 positive breast cancer patients with clinical stage T1c, lymph node negative and receiving Taxanes combined with double target neoadjuvant therapy admitted to the center from January 1, 2019 to December 31, 2024. Patients of the same type were prospectively included from January 1, 2025 to December 31, 2028. Objective to evaluate the efficacy and safety of Taxanes combined with double target neoadjuvant therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak piersi z dodatnim wynikiem HER2 potwierdzony biopsją w szpitalu
- •Wczesny etap choroby (T1c, N0, M0)
- •Leczenie w szpitalu z dostępnymi dokumentami hospitalizacji
- •Podpisana zgoda na udział w badaniu kohortowym
- •Decyzja lekarza o dodaniu chemioterapii w leczeniu uzupełniającym
✗ Disqualifies
- •Brak pełnych danych klinicznych i badań (zdjęcia, wyniki biopsji)
- •Rak piersi z przerzutami lub obustronny rak piersi
- •Jednoczesne uczestnictwo w innych badaniach klinicznych
- •Stosowanie innych schematów leczenia niż zaplanowany
Simplified criteria — AI translation
Trial details
- Last updated (source)
- December 9, 2024
- Sex
- No restrictions
Locations (1)
Peking University People's Hospital
Beijing, China
Trial contact
yuan peng, doctor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.